Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials
Figure 2
Representative illustration of immunological analysis in patients 3 and 15 who were treated with survivin-2B80–88 plus IFA with IFN alpha. Tetramer and ELISPOT analyses before and after vaccinations. The number in the tetramer analysis indicates survivin-2B80–88 peptide-specific CD8+ T cells among 104 CD8+ T cells. ELISPOT: enzyme-linked immunosorbent spot; HIV: human immunodeficiency virus; HLA: human leukocyte antigen; IFA: incomplete Freund’s adjuvant; IFN: interferon.
